Hong Kong Stock Market Moves | Hengrui Bio-Pharmaceutical (01801.HK) opens over 4% higher after results, first half-year profit of 834 million yuan, solidifying leading advantage in tumor product portfolio.

According to the Zhitong Financial APP, Xinda Biology post-performance soared more than 4%, up 4.29% as of the time of publication, reporting 94.9 Hong Kong dollars, with a turnover of 50.6292 million Hong Kong dollars.